Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr709 Inhibitors

Olr709 inhibitors are a specialized category of chemical compounds known for their ability to specifically target and modulate the activity of the Olr709 receptor, a member of the olfactory receptor family. These receptors, typically found in the olfactory epithelium, are integral to the complex processes of odor detection and signal transduction. Olr709 receptors belong to the G-protein coupled receptor (GPCR) superfamily, which is characterized by their seven transmembrane alpha-helical structures. Upon binding of an appropriate ligand, these receptors undergo conformational changes that activate intracellular G-proteins, initiating a cascade of downstream signaling events. Inhibitors of Olr709 can therefore modulate the initial stages of olfactory signal transduction by preventing the binding of natural ligands or by stabilizing the receptor in an inactive conformation.

The study and development of Olr709 inhibitors involve intricate chemical design and synthesis, often requiring a detailed understanding of receptor-ligand interactions at the molecular level. These inhibitors can be classified based on their structural features, such as small molecules, peptides, or even engineered proteins, each designed to achieve high specificity and affinity for the Olr709 receptor. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking simulations play crucial roles in elucidating the binding modes and structural conformations of these inhibitors. Furthermore, functional assays and electrophysiological studies are employed to assess the efficacy and potency of these compounds in modulating olfactory receptor activity. The insights gained from these studies not only advance our fundamental understanding of olfactory receptor function but also contribute to the broader field of chemical biology, where selective receptor modulation is a key area of research.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Beta-adrenergic antagonist, might modulate GPCR activity affecting Olr709.

Carvedilol

72956-09-3sc-200157
sc-200157A
sc-200157B
sc-200157C
sc-200157D
100 mg
1 g
10 g
25 g
100 g
$124.00
$240.00
$530.00
$999.00
$1530.00
2
(1)

Beta-adrenergic antagonist with alpha-1 blocking activity, potentially influencing Olr709 signaling.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$51.00
$171.00
$530.00
2
(1)

Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr709.

Labetalol

36894-69-6sc-484723
50 mg
$180.00
(0)

Combined alpha and beta blocker, might indirectly affect GPCR pathways including Olr709.

Pindolol

13523-86-9sc-204847
sc-204847A
100 mg
1 g
$194.00
$760.00
(1)

Beta-adrenergic antagonist, could influence GPCR-mediated signaling pathways related to Olr709.

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Beta-adrenergic agonist, could indirectly affect Olr709 through GPCR modulation.

Atropine

51-55-8sc-252392
5 g
$204.00
2
(1)

Muscarinic acetylcholine receptor antagonist, might influence GPCR signaling pathways including Olr709.

Salmeterol

89365-50-4sc-224277
sc-224277A
10 mg
50 mg
$186.00
$562.00
1
(1)

Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr709.

Alprenolol

13655-52-2sc-507469
50 mg
$130.00
(0)

Beta blocker, could indirectly influence GPCR signaling pathways including Olr709.